配对卵巢癌全面基因组测序揭示临床试验资格判定基因不一致
研究分析50例卵巢癌患者配对肿瘤样本的全面基因组测序结果,比较原发与复发样本间突变事件变化。多数样本基因组改变稳定,但23%患者第二样本出现影响临床试验资格的基因突变或拷贝数变异,部分用于分子靶向试验入选标准的基因存在不一致。
要点
- 配对卵巢癌样本总体基因组改变稳定,突变负荷、微卫星状态和杂合性缺失多一致。
- 基因突变一致性73%(32/44),拷贝数变异一致性较低51%(18/35)。
- 23%患者第二样本出现影响临床试验资格的基因突变或拷贝数变异。
核心结论
- 配对卵巢癌样本显示基因组改变随时间总体稳定,但部分用作分子靶向临床试验入选标准的基因存在不一致。
研究设计与样本
- 对Clearity基金会数据存储库中50例卵巢癌患者的配对FFPE肿瘤样本DNA行杂交捕获下一代测序,最多检测315个基因。
- 分析基因组突变、拷贝数变异、微卫星状态、肿瘤突变负荷和杂合性缺失,并比较同一患者样本间图谱。
- 6对样本因质量差被排除出所有分析,9对从拷贝数变异或杂合性缺失分析中排除。
主要发现
- 44例患者以晚期为主(34例,77%)、浆液性组织学为主(31例,70%),中位接受3种干预治疗方案(范围1-13)。
- 分析22对原发与复发样本及22对复发肿瘤样本,每样本中位检出2个基因组突变(范围0-5)和1个拷贝数变异(范围0-6)。
- 肿瘤突变负荷、微卫星状态和杂合性缺失结果在配对样本间大多一致。
- 基因组突变在多数配对中一致(32/44,73%),拷贝数变异一致性较低(18/35,51%)。
- 未检测到治疗相关基因组突变变化,但23%患者第二样本存在影响临床试验资格的基因组突变或拷贝数变异。
关键数值与推荐
- 基因组突变一致性:32/44对(73%)一致。
- 拷贝数变异一致性:18/35对(51%)一致。
- 23%患者第二样本存在影响临床试验资格的基因组突变或拷贝数变异。
临床怎么用
- 作者认为,在考虑检测成本和潜在临床获益后,若认为分子靶向试验资格重要,重复肿瘤检测可能有用。
局限性
- 6对样本因质量差被排除出所有分析,9对从拷贝数变异或杂合性缺失分析中排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time. METHODS: DNA from paired FFPE tumor samples from 50 ovarian cancer patients in the Clearity Foundation Data Repository was analyzed for genomic mutations (GM), copy number alterations (CNA), microsatellite status (MS), tumor mutation burden (TMB), and loss of heterozygosity (LOH) by hybrid-capture, next-generation sequencing of up to 315 genes. Genomic profiles were compared between samples from the same patient. Poor quality results excluded 6 pairs from all analyses and 9 from CNA or LOH. RESULTS: Forty-four patients with predominantly advanced stage disease (34, 77%) and serous histology (31, 70%) received a median of 3 intervening treatment regimens (range 1-13). Analysis of 22 primary and recurrent sample pairs and 22 recurrent tumor pairs detected a median of 2 GM (range 0-5) and 1 CNA (range 0-6)/sample. TMB, MS, and LOH results were mostly concordant across paired samples. GM were consistent across most pairs [32/44 (73%) concordant], while CNA concordance was less [18/35 (51%)]. No changes were detected in therapeutically relevant GM, but 23% of patients had GM or CNA in the second sample that affect clinical trial eligibility. CONCLUSIONS: Paired ovarian cancer samples demonstrate stable genomic alterations across time. However, discordance was observed for some genes used as eligibility criteria for molecularly targeted clinical trials. Repeat tumor testing may be useful in cases where eligibility for such trials is deemed important after consideration of testing costs and potential clinical benefit.
引用
- Fehniger JE, Berger AA, Juckett L, et al. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. Gynecol Oncol. 2019. PMID: 31703812. doi:10.1016/j.ygyno.2019.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。